# US 8,278,111 B2 · Metal abstraction peptide (MAP) tag and associated methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,111 B2
- Document ID: US8278111B2
- Status: Granted
- Kind: B2
- Application number: 13/341,223
- Filed: 2011-12-30
- Published: 2012-07-12
- Granted: 2012-10-02
- Earliest claimed: 2008-05-13
- Assignees: University of Kansas
- Inventors: Jennifer Ann Stowell Laurence; Anthony Andrew Vartia; Mary Elizabeth Krause
- Web page: https://patentgrep.com/patent/US8278111B2

## CPC

- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 35/00: Antineoplastic agents
- C07K 5/0819: {with the first amino acid being acidic}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions comprising a tripeptide having the sequence XC1C2; wherein X is any amino acid such that XC1C2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C1 and C2 are the same or different; and wherein C1 and C2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC1C2 complexes and methods for forming such complexes.

## Claims

### Claim 1

A composition comprising:
(a) a tripeptide having a sequence XC1C2,
wherein X is any natural or non-natural amino acid or amino acid analog,
and further wherein C1 and C2 are each individually chosen from a cysteine and a sulfur-containing alpha or beta amino acid; and
(b) a metal atom or ion bound to the sequence XC1C2,
wherein the metal atom or ion is bound in a square planar or square pyramidal orientation.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said peptide is linked to a polypeptide, an antibody, a growth factor, or a carbohydrate.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said metal is uranium.

### Claim 4 (depends on 1)

The composition of claim 1, wherein C1 and C2 are each cysteine.

### Claim 5 (depends on 1)

The composition of claim 1, wherein X is chosen from asparagine, glutamine, histidine, lysine, and arginine.

### Claim 6 (depends on 1)

A method of imaging biological tissue comprising administering a composition according to claim 1 to biological tissue and obtaining an image of said biological tissue.

### Claim 7 (depends on 1)

The composition of claim 1, wherein X is chosen from glutamine, histidine, and lysine.

### Claim 8 (depends on 1)

The composition of claim 1, wherein said metal is selected from a Group 6, Group 7, Group 8, and Group 9 metal.

### Claim 9 (depends on 1)

The composition of claim 1, wherein said peptide is isolated and purified.

### Claim 10 (depends on 1)

The composition of claim 1, wherein said peptide is linked to a growth factor or a carbohydrate.

### Claim 11 (depends on 1)

The composition of claim 1, wherein said peptide is linked to an antibody.

### Claim 12 (depends on 11)

The composition of claim 11, wherein said antibody targets cancer cells.

### Claim 13 (depends on 1)

The composition of claim 1, wherein said metal is selected from a Group 3 metal, a Group 5 metal, a Group 6 metal, a Group 7 metal, a Group 8 metal, a Group 9 metal, a Group 10 metal, a Group 11 metal, a Group 12 metal, a Group 13 metal, a Group 14 metal, and a Group 15 metal.

### Claim 14 (depends on 13)

The composition of claim 13, wherein said metal is selected from a Group 5, Group 10, Group 11, and Group 12 metal.

### Claim 15 (depends on 14)

The composition of claim 14, wherein said metal is a Group 5 metal.

### Claim 16 (depends on 15)

The composition of claim 15, wherein said Group 5 metal is vanadium.

### Claim 17 (depends on 14)

The composition of claim 14, wherein said metal is a Group 10 metal.

### Claim 18 (depends on 17)

The composition of claim 17, wherein said Group 10 metal is selected from the group consisting of Ni, Pd, and Pt.

### Claim 19 (depends on 14)

The composition of claim 14, wherein said metal is a Group 11 metal.

### Claim 20 (depends on 19)

The composition of claim 19, wherein said Group 11 metal is selected from the group consisting of Cu, Ag, and Au.

### Claim 21 (depends on 14)

The composition of claim 14, wherein said metal is a Group 12 metal.

### Claim 22 (depends on 21)

The composition of claim 21, wherein said Group 12 metal is selected from the group consisting of Zn, Cd, and Hg.

### Claim 23 (depends on 1)

The composition of claim 1, wherein said composition is selected from the group consisting of imaging compositions and therapeutic compositions.

### Claim 24 (depends on 23)

The composition of claim 23, wherein said composition is an imaging composition.

### Claim 25 (depends on 24)

The composition of claim 24, wherein said composition is an imaging composition formulated for use in an imaging technique selected from the group consisting of Computed Tomography (CT), Magnetic Resonance Imaging (MRI), ultrasound, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Nuclear Magnetic Resonance (NMR), Electron Paramagnetic Resonance (EPR), electron microscopy, and fluorescence imaging.

### Claim 26 (depends on 25)

The composition of claim 25, wherein said imaging technique is selected from the group consisting of PET and SPECT imaging.

### Claim 27 (depends on 23)

The composition of claim 23, wherein said composition is a therapeutic composition.

### Claim 28 (depends on 27)

The composition of claim 27, wherein said therapeutic composition is formulated as a chemotherapy composition.

### Claim 29 (depends on 28)

The composition of claim 28, wherein said chemotherapy composition is formulated for targeted delivery to a cancer cell.

### Claim 30

A method of preparing a metal-peptide complex comprising:
i) exposing a metal atom or ion to a chelating agent in solution or on a solid support; and
ii) binding a peptide including the sequence XC1C2 with the metal atom or ion to form a metal-XC1C2 complex; wherein X is any non-cysteine amino acid; and wherein C1 and C2 are the same or different; and wherein C1 and C2 individually are chosen from a cysteine and a cysteine-like normatural amino acid;
wherein said metal atom or ion is bound within the sequence XC1C2 in a square planar orientation or square pyramidal orientation; and
wherein said chelating agent is linked to a solid support.

### Claim 31

A method of preparing a metal-peptide complex comprising:
i) exposing a metal atom or ion to a chelating agent in solution or on a solid support; and
ii) binding a peptide including the sequence XC1C2 with the metal atom or ion to form a metal-XC1C2 complex; wherein X is any non-cysteine amino acid; and wherein C1 and C2 are the same or different; and wherein C1 and C2 individually are chosen from a cysteine and a cysteine-like normatural amino acid;
wherein said metal atom or ion is bound within the sequence XC1C2 in a square planar orientation or square pyramidal orientation; and
wherein said chelating agent is selected from the group consisting of iminodiacetic acid (IDA) and nitrilotriacetic acid (NTA).
